Immunotherapeutic approaches for small-cell lung cancer

Area of Science:

• Oncology
• Immunotherapy
• Pulmonology

Background:

• Immune-checkpoint inhibitors (ICIs) are approved for small-cell lung cancer (SCLC) in first- and third-line settings.
• Atezolizumab plus chemotherapy improves overall survival (OS) in the first-line setting for SCLC.
• While promising responses are seen in relapsed SCLC, randomized trials haven't shown significant OS improvement over chemotherapy.

Purpose of the Study:

• To review the clinical efficacy of ICIs in SCLC.
• To discuss emerging evidence on predictive biomarkers for ICI therapy in SCLC.
• To summarize ongoing clinical trials involving ICIs and other immunotherapies for SCLC.

Main Methods:

• Review of clinical trial data on ICI efficacy in SCLC.
• Analysis of biomarker studies, including PD-L1 expression and tumor mutational burden.
• Compilation of information on current and future clinical trials in SCLC immunotherapy.

Main Results:

• ICIs have demonstrated improved OS in SCLC patients after decades without significant progress.
• PD-L1 expression is not a reliable predictive biomarker in SCLC due to low/absent expression.
• Blood-based tumor mutational burden lacked predictive value in first-line atezolizumab plus chemotherapy trials.

Conclusions:

• ICIs represent a significant advancement in SCLC treatment, improving overall survival.
• Identifying reliable predictive biomarkers remains a critical unmet need for guiding ICI therapy in SCLC.
• Further research is essential to determine optimal therapeutic strategies and biomarkers for SCLC immunotherapy.